TDP-43 specific binding molecules
Provided are novel TAR DNA-binding proteins of 43 kDa (“TDP-43”)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.
1. A method of reducing the accumulation of pathological TDP-43 deposits or reducing pathological TAR-DNA-binding protein 43 kDa (TDP-43) distribution in a human subject in need thereof, comprising administering to the subject an effective amount of an anti-TDP-43 monoclonal antibody comprising a heavy chain variable (VH) region comprising the amino acid sequences of SEQ ID NO:131 (VH CDR1), SEQ ID NO:132 (VH CDR2), and SEQ ID NO:133 (VH CDR3) and a light chain variable (VL) region comprising the amino acid sequences of SEQ ID NO:135 (VL CDR1), SEQ ID NO:136 (VL CDR2), and SEQ ID NO:137 (VL CDR3).
2. The method of claim 1 , wherein the VH is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:130.
3. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130.
4. The method of claim 1 , wherein the VL is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO:134.
5. The method of claim 1 , wherein the VL comprises the amino acid sequence of SEQ ID NO:134.
6. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
7. The method of claim 1 , wherein the antibody is a human antibody, humanized antibody, chimeric antibody, or murinized antibody.
8. The method of claim 1 , wherein the antibody is an antigen binding antibody fragment.
9. The method of claim 8 , wherein the antigen binding antibody fragment is selected from the group consisting of a single chain Fv fragment (scFv), a F(ab′) fragment, a F(ab) fragment, and a F(ab′)2 fragment.
10. The method of claims 1 , wherein the antibody is attached to a drug.
11. The method of any one of claims 1 to 9 , wherein the antibody is a component of a composition comprising a pharmaceutically acceptable carrier.
12. The method of claim 11 , further comprising administering an additional agent useful for treating a TDP-43 proteinopathy.
13. The method of claim 1 , wherein the subject is suffering from a TDP-43 proteinopathy selected from the group consisting of argyrophilic grain disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), ALS-Parkinsonism dementia complex of Guam, corticobasal degeneration, Dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia, frontotemporal lobar degeneration with ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, Parkinson's disease dementia, Parkinson-dementia complex in Kii peninsula and Pick's disease.
14. The method of claim 13 , wherein the subject is suffering from Alzheimer's disease.
15. The method of claim 14 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
16. The method of claim 13 , wherein the subject is suffering from amyotrophic lateral sclerosis (ALS).
17. The method of claim 16 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
18. The method of claim 13 , wherein the subject is suffering from frontotemporal lobar degeneration (FTLD).
19. The method of claim 18 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
20. The method of claim 13 , wherein the subject is suffering from Parkinson's disease.
21. The method of claim 20 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
22. A method of reducing the number or frequency of TAR-DNA-binding protein 43kDa (TDP-43) positive inclusion-positive neurons in the brain or spinal cord in a human subject in need thereof, comprising administering to the subject an effective amount of an anti-TDP-43 monoclonal antibody, comprising
a heavy chain variable (VH) region comprising the amino acid sequences of SEQ ID NO:131 (VH CDR1); SEQ ID NO:132 (VH CDR2), and SEQ ID NO:133 (VH CDR3)
and a light chain variable (VL) region comprising the amino acid sequences of SEQ ID NO:135 (VL CDR1), SEQ ID NO:136 (VL CDR2), and SEQ ID NO:137 (VL CDR3).
23. The method of claim 22 , wherein the subject is suffering from Alzheimer's disease.
24. The method of claim 23 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
25. The method of claim 22 , wherein the subject is suffering from amyotrophic lateral sclerosis (ALS).
26. The method of claim 25 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
27. The method of claim 22 , wherein the subject is suffering from frontotemporal lobar degeneration (FTLD).
28. The method of claim 27 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
29. The method of claim 22 , wherein the subject is suffering from Parkinson's disease.
30. The method of claim 29 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
31. The method of claim 22 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.
32. A method of reducing the amount or concentration of neuritic TAR-DNA-binding protein 43kDa (TDP-43) protein in the brain or spinal cord in a human subject in need thereof, comprising administering to the subject an effective amount of an anti-TDP-43 monoclonal antibody comprising
a heavy chain variable (VH) region comprising the amino acid sequences of SEQ ID NO:131 (VH CDR1), SEQ ID NO:132 (VH CDR2), and SEQ ID NO:133 (VH CDR3)
and a light chain variable (VL) region comprising the amino acid sequences of SEQ ID NO:135 (VL CDR1), SEQ ID NO:136 (VL CDR2), and SEQ ID NO:137 (VL CDR3).
33. The method of claim 32 , wherein the VH comprises the amino acid sequence of SEQ ID NO:130 and the VL comprises the amino acid sequence of SEQ ID NO:134.